| Drug Name |
Abatacept |
| Drug ID |
BADD_D00012 |
| Description |
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077). |
| Indications and Usage |
For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children. |
| Marketing Status |
Prescription |
| ATC Code |
L04AA24 |
| DrugBank ID |
DB01281
|
| KEGG ID |
D03203
|
| MeSH ID |
D000069594
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0EW4L
|
| NDC Product Code |
0003-2814; 0003-2818; 0003-2188; 70409-2187; 0003-2187 |
| Synonyms |
Abatacept | CTLA-4-Ig | Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin | Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin | CTLA4-Ig | CTLA4-Ig Immunoconjugate | CTLA4 Ig Immunoconjugate | Immunoconjugate, CTLA4-Ig | CTLA4-Fc | BMS224818 | BMS-224818 | BMS 224818 | Belatacept | Orencia | BMS 188667 | BMS-188667 | BMS188667 | LEA29Y | Nulojix |
